Home > Healthcare > Medical Devices > Diagnostic Devices > Tissue Diagnostics Market

Tissue Diagnostics Market Trends

  • Report ID: GMI3754
  • Published Date: Jun 2023
  • Report Format: PDF

Tissue Diagnostics Market Trends

Growing adoption of unhealthy diet including excessive fat and sugar content coupled with lack of physical exercise has escalated number of people suffering from chronic conditions such as diabetes and cancer. Globally, cancer ranks as a primary cause of mortality and a significant roadblock to raising life expectancy. For instance, according to the World Health Organization (WHO) estimates, cancer is the one of the top causes of death before the age of 70 in 23 countries and the first/second main cause in 112 of 183 countries. The fact that cancer is becoming more prevalent as a leading cause of death is partially as a result of the notable declines in stroke and coronary heart disease mortality rates worldwide.

Authors: Mariam Faizullabhoy , Subodh Kharad

Frequently Asked Questions (FAQ) :

Global tissue diagnostics industry size was over USD 5 billion in 2022 and will reach more than USD 11 billion by 2032.

The digital pathology technology segment will witness a 8.6% CAGR between 2023 to 2032 due to an in the adoption of whole-slide imaging (WSI) by pathologists.

U.S. tissue diagnostics market will be valued at more than USD 3 billion by 2032 as to high incidence rate of cancer.

F. Hoffmann-La Roche Ltd., Siemens, Danaher, bioMérieux SA, Abbott Laboratories, QIAGEN, Becton Dickinson & Company, Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Inc, GE Healthcare, BioGenex, and Cell Signaling Technology, Inc.

Tissue Diagnostics Market Scope

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 12
  • Tables & Figures: 490
  • Countries covered: 31
  • Pages: 210
 Download Free Sample